IL4 and vitiligo: suggested that dupilumab-induced IL-4 inhibition leads to Th1/Th17 polarization, resulting in increased expression of IL-17, IL-2, TNF-α, and IFN-γ, which are implicated in the pathogenesis of vitiligo (47).